Income Statement
ENTERA BIO LTD.
ENTX
Performance Overview
Click any row in the table to add it to this chart
in millions USD
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY |
|---|---|---|---|---|---|
|
Revenue
|
0.04 | 0.18 | 0.00 | 0.13 | 0.57 |
|
Cost of Revenue
|
0.04 | 0.17 | 0.00 | 0.10 | 0.37 |
|
Gross Profit
|
0.00 | 0.01 | 0.00 | 0.03 | 0.20 |
|
Operating Expenses
|
11.53 | 9.59 | 8.89 | 13.05 | 12.42 |
|
Research & Development
|
6.00 | 4.50 | 4.51 | 5.85 | 6.77 |
|
Selling, General & Administrative
|
5.53 | 5.10 | 4.43 | 7.25 | 5.69 |
|
Other Operating Expenses
|
- | - | - | - | - |
|
Operating Income
|
-11.53 | -9.59 | -8.89 | -13.02 | -12.22 |
|
Non-Operating Income
|
0.09 | 0.06 | 0.03 | 0.08 | -0.03 |
|
Interest Income
|
- | - | - | - | - |
|
Interest Expense
|
- | - | - | - | - |
|
Other Non-Op Income / Expense
|
- | - | - | - | - |
|
Income Before Tax
|
0.00 | 0.05 | 0.01 | 0.07 | 0.12 |
|
Income Tax Expense
|
0.00 | 0.01 | 0.03 | 0.14 | -0.06 |
|
Non-Controlling Interest
|
- | - | - | - | - |
|
Net Income
|
-11.44 | -9.54 | -8.89 | -13.07 | -12.19 |
Supplemental
Per share data, derived & other items — not part of the income statement
in millions USD unless noted
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY |
|---|---|---|---|---|---|
|
Depreciation & Amortization
|
- | - | - | - | - |
|
EBITDA
|
-11.53 | -9.59 | -8.89 | -13.02 | -12.22 |
|
Earnings Per Share (Basic)
|
0.25 | 0.25 | 0.31 | 0.45 | - |
|
Diluted EPS
|
0.25 | 0.25 | 0.31 | 0.45 | - |
|
Weighted Average Shares
|
46.19 | 37.65 | 29.01 | 28.81 | - |
|
Diluted Weighted Avg Shares
|
46.19 | 37.65 | 29.01 | 28.81 | - |
|
Comprehensive Income
|
- | - | - | - | - |